Skip to main content
SpringerLink
Log in
Book cover

Bone Marrow Transplantation pp 55–77Cite as

Acute graft-versus-host disease

  • Chapter

  • 89 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 50))

Abstract

Acute graft-verus-host disease (GVHD) remains the major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT) despite the use of matched donors. Three quarters of patients who might benefit from transplantation lack matched donors and are unable to receive transplants because of severe GVHD seen with mismatched donors. GVHD has remained in important question for basic immunologists trying to understand the cellular events involved in GVHD and in the induction of donor-to-host immunologic tolerance following transplant. This chapter will cover first the scientific background of GVHD. The clinical spectrum of the disease, prophylaxis, and therapy will then be covered in greater detail.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barnes DWH, Loutit JF. Spleen protection: The cellular hypothesis. In: Radiobiology Symposium Liege, Bacq ZM, ed. Butterworth, London, 1955:134–135.

    Google Scholar 

  2. Cohen JA, Vos O, van Bekkum DW. The present status of radiation protection by chemical and biological agent in mammals. In: Advances in Radiobiology, de Hersey GC, Forssberg AG, Abbott JD, ed. Oliver and Body, Edinburgh, 1957:134–144.

    Google Scholar 

  3. Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplantation 1957; 4:67.

    CAS  Google Scholar 

  4. Santos GW, Cole JL. Effects of donor and host lymphoid and myeloid tissue injections in lethally x-irradiated mice treated with rat bone marrow. J Natl Cancer Inst 1958; 21:279–293.

    PubMed  CAS  Google Scholar 

  5. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures. 1966–7; 62:21–78.

    PubMed  Google Scholar 

  6. Grebe SC, Streilein JW. Graft-versus-host disease. Adv Immunol 1976; 22:119–221.

    PubMed  CAS  Google Scholar 

  7. Owens AH, Santos GW. The induction of graft-versus-host disease in mice treated with cyclophosphamide. J Exp Med 1968; 128:227–291.

    Google Scholar 

  8. Mathe G, Bernard J, deVries MJ. Nouveaux esqis de greffe de moelle asseuse homologue apres irradiation totale chez des enfants atteints de leucemie aigue en remission. Le probleme du syndrome secondaire chez l’homme. Rev Fe Etud Clin Biol 1960; 15:115–121.

    CAS  Google Scholar 

  9. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148:1687–1698.

    PubMed  CAS  Google Scholar 

  10. Korngold R, Sprent J. Lethal graft-versus-host disease across minor histocompatibility barriers in mice. Clin Haematol 1983; 12:681–693.

    PubMed  CAS  Google Scholar 

  11. Storb R, Weiden P, Graham T, Lerner K, Nelson N, Thomas E. Hematopoietic grafts between DLA-identical canine littermates following dimethylmyleran. 1977; 349–357.

    Google Scholar 

  12. Goulmy E, Gratama JW, Blokland E, Zwaan FE, Van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983; 302:159–161.

    PubMed  CAS  Google Scholar 

  13. Reinsmoen NL, Kersey JH, Bach FH. Detection of HLA restricted anti-minor histocompatibility antigens reactive cells from skin GVHD lesions. Hum Immunol 1984; 4:249–257.

    Google Scholar 

  14. Gluckman E, Devergie A, Sohier J, Saurat JH. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980; 1:253–254.

    PubMed  CAS  Google Scholar 

  15. Rappeport J, Reinherz E, Mihm M, Lopansii S, Parkman E. Acute graft-versus-host disease in recipients of bone marrow transplants from identical twin donors. Lancet 1979; 2:717–720.

    PubMed  CAS  Google Scholar 

  16. Thein SL, Goldman JM, Galton DA. Acute graft-versus-host diseas after autografting for chronic granulocytic leukemia in transplantation. Ann Interv Med 1981; 94:210–211.

    CAS  Google Scholar 

  17. Hood A, Vogelsang G, Black C, Farmer E, Santos GW. Acute fraft-versus-host disease following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123:745–750.

    PubMed  CAS  Google Scholar 

  18. Glazier A, Tutschka PJ, Farmer E, Santos GW. Graft-versus-host disease in cyclosporin A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158:1–8.

    PubMed  CAS  Google Scholar 

  19. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplanation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-la specificity including autoreactivity. J Exp Med 1985; 161:718–730.

    PubMed  CAS  Google Scholar 

  20. Weksler ME, Moody CE, Kozak RW. The autologous mixed lymphocyte reaction. Adv Immunol 1981; 31:271–312.

    PubMed  CAS  Google Scholar 

  21. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaj M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA, Doney K, Fefer A, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP. Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphocytic leukemia. Blood 1985; 65:1325–1334.

    PubMed  CAS  Google Scholar 

  22. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin for prophylaxis of graft-versus-host disease: A randomized trial in patients with leukemia treated with HLA-identical sibling matched grafts. Transplantation 1979; 27:227–230.

    PubMed  CAS  Google Scholar 

  23. Storb R, Prentice R, Buckner C, Clift R, Apelbaum F, Deeg J, Doney K, Hansen J, Mason M, Sanders J, Singer J, Sullivan K, Witherspoon R, Thomas ED. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings beneficial effect of protective environment. N Engl J Med 1983; 308:302–307.

    PubMed  CAS  Google Scholar 

  24. Vogelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: Clinical characteristics in the cyclosporine era. Medicine 1988; 67:163–164.

    PubMed  CAS  Google Scholar 

  25. Woodruff JM, Hansen JA, Good RA, Santos GW, Slavin RE. The pathology of graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Trans Proc 1976; 8:675–684.

    CAS  Google Scholar 

  26. Sale GE, Lerner KG, Barker A, Shulman HM, Thomas ED: The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977; 89:621–636.

    PubMed  CAS  Google Scholar 

  27. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974; 6:67–71.

    Google Scholar 

  28. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Growchow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Sarai R. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987, in press.

    Google Scholar 

  29. Bross DS, Tutschka PJ, Farmer ER, Beschorner WE, Brain HG, Mellits ED, Bias WB, Santos GW. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63:1265–1270.

    PubMed  CAS  Google Scholar 

  30. Storb R, Prentice R, Thomas ED. Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft-versus-host disease. J Clin Invest 1977; 59:625.

    PubMed  CAS  Google Scholar 

  31. Bortin MM. Acute graft-versus-host disease following bone marrow transplantation in humans: Prognostic factors. Transplant Proc 1987; 19:2655–2657.

    PubMed  CAS  Google Scholar 

  32. Zwann FE, Hermans T. Bone marrow transplantation for leukemia: European results in 264 cases. Exp Hematol 1982; 10:47.

    Google Scholar 

  33. Gale RP, Bortin M, Van Bekkum D, Biggs J, Dicke K, Gluckman E, Good R, Hoffmann, Kary H, Kersey J, Marmont A, Masaoka T, Rimm A, Van Rood J, Zwann F. Risk factors for acute graft versus-host-disease. Br J Haematol 1987; 67:397–406.

    PubMed  CAS  Google Scholar 

  34. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J. Female donors increase the risk of graft-versus-host disease. Br J Haematol 1986; 63:231–239.

    PubMed  CAS  Google Scholar 

  35. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckman CD, Storb R, Thomas ED, Hansen JA. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765–771.

    PubMed  CAS  Google Scholar 

  36. Storb R, Prentice R, Hansen JA, Thomas ED. Association between HLA-B antigens and acute graft-versus-host disease. Lancet 1983; 2:816.

    PubMed  CAS  Google Scholar 

  37. Hopkins KA, Vogelsang GB, Delaney NL, Gultette DL, Santos GW, Bias WB. Implication of gene distal to HLA A in the etoloty of graft-versus-host disease. Transplant Proc, 1988, in press.

    Google Scholar 

  38. van Bekkum DW, Knaan S. Brief communication: Role of bacterial microflora in development of intestinal legions from graft-versus-host reactions. J Natl Cancer Inst 1977; 58:787–789.

    PubMed  Google Scholar 

  39. Storb B. Graft-versus-host disease after marrow transplantation. In: Transplantation: Approaches to Graft Rejection, Meryman HT, ed. Alan R Liss, New York, 1986: 139–157.

    Google Scholar 

  40. Ramsay NK, Kersey JH, Robinson LL, McGlave PB, Woods WG, Krivit W, Kin TH, Goldman AI, Nesbit ME. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306:392–397.

    PubMed  CAS  Google Scholar 

  41. Vogelsang GB, Hess AD, Berkman A, Tutschka P, Farmer E, Converse P, Santos GW. An in vitro predictive test for graft-versus-host disease in patients with genotypic HLA-identical bone marrow transplants. N Engl J Med 1985; 313:645–650.

    PubMed  CAS  Google Scholar 

  42. Delmonte L, O’Reilly RJ, Kirkpatrick D, Kapoor N. In vitro model for detection of allo-reactivity between HLA-matched donor-host pairs. Transplantation 1982; 34:100–103.

    PubMed  CAS  Google Scholar 

  43. Bagot M, Cordonnier C, Tilkin FF, Heslan M, Vernan TT, Bubertret L, Levy JP. A possible predictive test for graft-versus-host disease in bone marrow graft recipients: The mixed epidermal cell-lymphocyte reaction. Transplantation 1986; 41:316–319.

    CAS  Google Scholar 

  44. Elfenbein G, Goedect T, Graham-Pole J, Skoda-Smith S, Gross S, Weiner R. Is prophylaxis against acute graft-versus-host disease necessary if treatment is effective and survival is not impaired? ASCO 1986; 5:643.

    Google Scholar 

  45. Lazarus HM, Coccia PF, Herzig RH, Graham-Pole J, Gross S, Strandjord S, Gordon E, Cheving N, Warkentin P, Spitzer TR, Warm S. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in bone marrow transplant patients. Blood 1984; 64:215–220.

    PubMed  CAS  Google Scholar 

  46. Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H, Sale G, Martin P, Witherspoon R, Appelbaum F, Doney K, Stewart P, Meyers J, McDonald GB, Weiden P, Fefer A, Buckmen CD, Storb R, Thomas ED. Hyperacute graft-versus-host disease in patients not given immunosuppression after allogeneic marrow transplant. Blood 1986; 67:1172–1175.

    PubMed  CAS  Google Scholar 

  47. Santos GW, Owens AH. A comparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats. Bull Hopkins Hosp 1965; 116:327–329.

    PubMed  CAS  Google Scholar 

  48. Thomas ED, Storb R, Clift RA. Bone marrow transplantation. N Engl J Med 1975; 292: 832–843.

    PubMed  CAS  Google Scholar 

  49. Thomas ED, Storb R, Clift RA. Bone marrow transplantation. N Engl J Med 1975; 292:895–902.

    PubMed  CAS  Google Scholar 

  50. Tutschka PJ, Farmer E, Beschorner WE, Mundord L, Harrison D, Santos GW. Therapy of acute graft-versus-host disease (GVHD-Baltimore experience) Exp Hematol 1981; 9(Suppl 9):126.

    Google Scholar 

  51. Doney KC, Weiden PL, Storb R, Thomas ED. Failure of early administration of anti-thymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981; 31:141–143.

    PubMed  CAS  Google Scholar 

  52. Filipovich AH, Krawczak CL, Kersey J, McGlave P, Ramsey N, Goldman A, Goldstein G. Graft-versus-host disease prophylaxis with anti-T cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone marrow transplantation. Br J Haematol 1985; 60:143–152.

    PubMed  CAS  Google Scholar 

  53. Hess AD, Colombani PM, Esa AH. Cyclosporine and the immune response: Basic aspects. CRC Crit Rev Immunol 1986; 6:123–149.

    CAS  Google Scholar 

  54. Tutschka PJ, Beschorner WE, Allison AC, Burns WH, Santos GW. Use of cyclosporin A in allogeneic bone marrow transplantation in the rats. Nature 1979; 280:148–151.

    PubMed  CAS  Google Scholar 

  55. Powles PL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett A, Jameson B, Lawler SD, Kay HEM, Laudson D, McElwain TJ, Alexander P. Cyclosporine A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; 1:327–329.

    PubMed  CAS  Google Scholar 

  56. Gluckman E, Devergie A, Arcese W, Gerotta I, Borrin M, Bernard J. Cyclosporine A prophylactic treatment of graft-versus-host disease in human allogeneic bone marrow transplant: Preliminary results. Blut 1980; 41:182–186.

    Google Scholar 

  57. Gratwohl A, Osterwald B, Ruggers D, Missen C, Cornu P, Speck B. Prophylaxis of graft-versus-host disease with cyclosporine A. Blut 1980; 41:180–181.

    Google Scholar 

  58. Tutschka PJ, Beschorner WE, Hess AD, Santos GW. Cyclosporine A to prevent graft-versus-host disease. A pilot study in 22 patients receiving allogeneic marrow transplants. Blood 1983; 61:318–325.

    PubMed  CAS  Google Scholar 

  59. Barrett A, Kendra J, Lucas C, Joss D, Joshi R, Pendharkar P, Jones K. Cyclosporine A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J 1982; 285:161–165.

    Google Scholar 

  60. Gratwohl A, Speek B, Wenk M, Forster I, Muller M, Ostrerwalder B, Nissen C, Follath F. Cyclosporine in human bone marrow transplantation. Transplant 1983; 36:40–44.

    CAS  Google Scholar 

  61. Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA, Clift RA, Doney KC, Flournoy N, Kennedy MS, Loughran TP, McGuffin RW, Sale GE, Sanders JR, Singer JW, Stewart PS, Sullivan KM, Witherspoon RP. Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine-versus-methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66:698–702.

    PubMed  CAS  Google Scholar 

  62. Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, Dodds A. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplant. Transplant Proc 1986; 18:253–255.

    PubMed  CAS  Google Scholar 

  63. Ringden O, Backman L, Lonngquist B, Heimdahl A, Lindholm A, Bolme P, Gahiton G. A randomized trial comparing use of cyclosporine and methotrexate for graft vs. host disease prophylaxis in bone marrow transplant recipients with hematologic malignanies. Bone Marrow Transplant 1986; 1:41–51.

    PubMed  CAS  Google Scholar 

  64. Jacobs P. Cyclosporine pre treatment of both donor and recipients undergoing allogeneic bone marrow transplant. Scand J. Haematol 1985; 35:386–393.

    PubMed  CAS  Google Scholar 

  65. Irle C, Deeg HG, Buckner CD, Kennedy N, Clift R, Storb R, Appelbaum F, Beatt YP Bensinger W, Doney K, Cheever M, Fefer A, Greenberg P, Hill R, Martin P, McGriffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Marrow transplantation for leukemia following total body irradiation: A comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9:1255–1266.

    PubMed  CAS  Google Scholar 

  66. Bacigalupo A, Frassoni F. VanLint M, Raffo M, Vitale V, Corbetta G, Cheirchetti S, Marmont A. Cyclosporine A in marrow transplantation for leukemia and aplastic anemia. Exp Hematol 1985; 13:244–248.

    PubMed  CAS  Google Scholar 

  67. Storb R, Deeg HJ, Withehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Strout P, Sullivan K, Witherspoon R, Yee G, Thomas ED. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729–735.

    PubMed  CAS  Google Scholar 

  68. Clift RA, Backner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M, Beatty PS, Bensinger W, Cheever M, Deeg J, Doney K, Fefer A, Greenberg P, Hansen J, Hackman K, Hill R, Martin P, Meyers J, McGriffin R, Neiman P, Sale G, Witherspoon R. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2:243–258.

    PubMed  CAS  Google Scholar 

  69. Santos GW, Tutschka PJ, Brookmeyer R, Sarai R, Beschorner WE, Bias WB, Braine HG, Burns WH, Farmer ER, Hess AD, Kaizer H, Mellits D. Sensenbrenner L, Stuart R, Yeager A. Cyclosporine plus methylprenisolone versus cyclophosphamide plus methyl-prednisolone as prophylaxis for graft-versus-host disease: A radomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1:21–28.

    Google Scholar 

  70. Forman SJ, Blume KG, Krance RA, Miner PJ, Metler GE, Hill LR, O’Donnell MR, Nademanee AP, Snyder DS. A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: Methotrexate/prednisone versus cyclosporine/ prednisone. Transplant Proc 1987; 21:2605–2607.

    Google Scholar 

  71. Storb R, Deeg JH, Whitehead J, Farewell V, Appelbaum FR, Beatty P, Bensinger W, Buckner CD, Clift RA, Hanson JA, Lum L, Martin P, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Marrow transplantation for leukemia and aplastic anemia, two control trials of combination of methotrexate and cyclosporine versus cyclosporine alone or methotrexate alone for prophylaxis of acute graft-versus-host disease. Transplant Proc 1987; 19:2608–2613.

    PubMed  CAS  Google Scholar 

  72. Tutschka PJ, Copelan EA. Prevention of severe GVHD employing cyclosporine in HLA-matched marrow transplants for leukemia. Exp Hematol 1987; 15:355.

    Google Scholar 

  73. Figuera A, Camara R, Fernandex J. Comparison of two regimens of graft versus host disease prophylaxis in 41 bone marrow transplant patients. Bone Marrow Transplant 1987; 2(Suppl 1):163.

    Google Scholar 

  74. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O’Reilly RJ. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatable parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983: 61:341–348.

    PubMed  CAS  Google Scholar 

  75. DeWitte T, Hoogenhout J, dePauw B, Holdrinet R, Janssen J, Wessels J, vanDaal W, Hustin XT, Haanen C. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplants. Blood 1986; 67:1302–1308.

    CAS  Google Scholar 

  76. Wagner JE, Donnenberg AD, Noga SJ, Gao IK, Cremo CA, Yin HJ, Vogelsang GB, Rowley S, Sarai R, Santos GW. Lymphocyte depletion of donor bone marrow by counter-flow centrifugal elutriation. Results of a phase I clinical trial. Blood, 1988, in press.

    Google Scholar 

  77. Filipovich AH, McGlave PB, Ramsay NKC, Golstein G, Warkentin PI, Kersey JH. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1982; 1:1266–1269.

    PubMed  CAS  Google Scholar 

  78. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66:664–672.

    PubMed  CAS  Google Scholar 

  79. Prentice HG, Blalock HA, Janossy G, Skegg D, Bradstock KF, Goldstein G. Use of anti T cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet 1982; 1:700–703.

    PubMed  CAS  Google Scholar 

  80. Haas RJ, Janka G, Netzel B, Rodt H, Thierfelder S, Helmig M, Eife R, Belohradsky B, Kolb H, Betke K. Antibody incubation of human marrow graft for prevention of graft-versus-host disease. Blut 1980; 40:387–397.

    PubMed  CAS  Google Scholar 

  81. Prentice H, Janossy G, Trejdosiewicz L, Panjwani D, Graphakos S, Ivory K, Blacklock H, Gilmore M, Tidman N, Skeggs D, Ball S, Patterson J, Hoffbrand A. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukemic marrow transplant recipients. Lancet 1984; 1:472–476.

    PubMed  CAS  Google Scholar 

  82. Rowley S, Stuart R, Hess A, Donnenberg A, Sarai R, Santos GW. Prevention of acute graft-versus-host disease (GHVD) by methylprednisolone (MP) incubation of donor bone marrow. Blood 1985; 66(Suppl 1):261.

    Google Scholar 

  83. Herve P, Flesch M, Cahn J, Racadot E, Plouvier E, Lamy B, Rozenbaum A, Noir A, Lecontedesfloris R, Peters A. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. Transplantation 1985; 39:138–143.

    PubMed  CAS  Google Scholar 

  84. Trigg ME, Billing R, Sandel P, Exten R, Hong R, Bozdech M, Horwitz S, Finlay J, Moen R, Longo W, Erickson C, Peterson A. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. Cancer Treat Rep 1985; 69:377–386.

    PubMed  CAS  Google Scholar 

  85. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky G, Winston D, Selch M, Elashoff R, Giorgi J, Wells J, Terasaki P, Billing T, Feig S. Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-versus-host. Ann. Intern Med 1986; 105:20–26.

    PubMed  CAS  Google Scholar 

  86. Apperly JF, Jones L, Arthur G, Yuo AP, Rassol F, Hale G, Waldmann H, Goldman JM. Incidence of relapse after T-cell deplated marrow transplant for chronic granulocytic leukemia in 1st chronic phase. Blood 1986; 68(Suppl 1):957.

    Google Scholar 

  87. Henslee PJ, Thompson JS, Ramond EH, Doukash A, Metcalfe, M, Marshall ME, McDonald JS. T cell depletion of HLA and haploidentical marrow reduces graft-versus-disease but may impair a graft-versus-leukemia effect. Transplant Proc 1987; 19:2701–2706.

    PubMed  CAS  Google Scholar 

  88. Slavin S, Or R, Naparstek G, Weiss L, Mumcuoglu M, Weshler Z, Brautbar H, Cividalli G, Glikson M, Hale G, Waldman H. Allogeneic bone marrow transplantation without graft-versus-host disease. True tolerance of graft against the host through depletion of donor T lymphocytes. Transplant Proc 1987; 19:2614–2615.

    PubMed  CAS  Google Scholar 

  89. Filipovich AH, Vallera DA, Youle RJ, Haake R, Blazer B, Arthur D, Neville D, Ramsay N, McGlave P, Kersey J. Graft-versus-host disease prevention in allogeneic bone marrow transplantation for histocompatible sibling. Transplantation 1987; 44:62–69.

    PubMed  CAS  Google Scholar 

  90. Racadot E, Herve P, Beaijian F, Vermont J, Flesh M, Plouvier E, Andreu G, Rio B, Philippe N, Souillet G, Pico J, Bodrgoni P, Ifrah N, Paitre M, Lutz P, Morizet J, Bernard A. Prevention of graft versus host disease in HLA-matched bone marrow transplantation for malignant disease. J Clin Oncol 1987; 5:426–435.

    PubMed  CAS  Google Scholar 

  91. Marqaninchi D, Blaise D, Rio B, Leblond V, Dreyfus F, Gluckman E, Guyotat D, Pico JL, Michaile M, Ifrah N. Impact of T cell depletion and outcome of allogeneic bone marrow transplantation for standard risk leukemia. Lancet 1987; 2:175–178.

    Google Scholar 

  92. Hect W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, Waldmann H, Heimpel H. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-hsot disease in allogeneic bone marrow transplantation. Br J Haematol 1986; 64:479–436.

    Google Scholar 

  93. Gilmore M, Patterson J, Ivory K, Bernner M, Graphakos S, Janossy G, Hofbrand A, Prentice H. Standardization of T-cell depletion in HLA matched bone marrow transplantation. Br J Haematol 1986; 64:69–75.

    PubMed  CAS  Google Scholar 

  94. Storb R, Gluckman R, Thomas ED, Buckner CD, Dlift RA, Fefer A, Glucksberg H, Graham TC, Johnson FL, Lerner KG, Nieman PE, Och SH. Treatment of established human graft-versus-host disease by anti-thymocyte globulin. Blood 1974; 44:57–75.

    Google Scholar 

  95. Prentice HG, Bateman S, Bradstock K, Hoffbrand A. High-dose methylprednisolone therapy in established acute graft-versus-host disease. Blut 1980; 41:175–177.

    Google Scholar 

  96. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic graft recipients: A randomized trial comparing anti-thymocyte globulin and corticosteroids. Am J Hematol 1981; 11:1–8.

    PubMed  CAS  Google Scholar 

  97. Kanojia MD, Anagnostou AA, Zander AR, Vellekoop L, Minnhaar G, Spitzer G, Dicke K. High dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adult. Transplantation 1984; 37:246–249.

    PubMed  CAS  Google Scholar 

  98. Kennedy MS, Deeg, HS, Storb R, Doney K, Sullivan KM, Witherspoon RP, Appelbaum FR, Stewart P, Sanders J, Buckner CD, Martin P, Weiden P, Thomas ED. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: A randomized study comparing corticosteroids and cyclosporine. Am J Med 1985; 78:978–983.

    PubMed  CAS  Google Scholar 

  99. Deeg HS, Lovghran TP, Storb R, Kennedy MS, Sullivan KM, Doney K, Appelbaum FR, Thomas ED. Treatment of human acute graft-versus-host disease with anti-thymic globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40:162–166.

    PubMed  CAS  Google Scholar 

  100. Kernan NA, Byers V, Brochstein J, Levy N, Scannon P, Dupont B, O’Reilly RJ. Anti-T cell ricin-A-chain immunotoxin for treatment of steroid resistant acute graft-versus-host disease. Blood 1986; 68(Suppl 1):1011.

    Google Scholar 

  101. Martin P, Shulman H, Schubach W, Hansen JA, Fefer A, Miller G, Thomas ED. Fatal Epstein Barr virus associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T cell antibody. Ann Intern Med 1984; 101:310–315.

    PubMed  CAS  Google Scholar 

  102. Remlinger K, Martin PJ, Hansen JA, Doney KC, Smith A, Deeg HJ, Sullivan K, Storb R, Thomas ED. Murine monoclonal anti-T cell antibodies for treatment of steroid resistant acute graft-versus-host disease. Human Immol 1984; 9:21–35.

    CAS  Google Scholar 

  103. Gluckman E, Devergie A, Varin F, Rabian C, D’Agay MF, Benbuan M. Treatment of steroid resistant acute graft-versus-host disease with a monoclonal Pan T OKT3 antibody. Exp Hematol 1984; 12(Suppl 15):66–67.

    Google Scholar 

  104. Atkinson K, Weiler T, Ryman W, Biggs J. PUVA therapy for drug resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1:277–286.

    Google Scholar 

  105. Byers V, Henslee P, Kernan N, Blazer B, Ginrich R, Phillips G, Antin J, Mischak R, O’Reilly, Scannon P. Therapeutic response to a pan-T lymphocyte monoclonal antibody-ricin A chain immunotoxin in steroid refractory graft versus host disease. Blood 1987; 70(Suppl 1):1071.

    Google Scholar 

  106. Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41:644–647.

    PubMed  CAS  Google Scholar 

  107. Vogelsang GB, Taylor S, Gordon G, Hess A. Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant Proc 1986; 18:904–906.

    CAS  Google Scholar 

  108. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED: Seattle Marrow Transplant Team. Anti-leukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1429–1533.

    Google Scholar 

  109. Weiden PL, Flournoy N, Thomas ED. Anti-leukemic effects of graft-versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1982; 306:392–397.

    Google Scholar 

  110. Hess AD, Vogelsang GB, Silanskis M, Friedman KA, Beschorner WE, Santos GW. Syngeneic graft-versus-host disease after allogeneic bone marrow transplantation and cyclo-sporine treatment. Transplant Proc 1988; 20:487–492.

    PubMed  CAS  Google Scholar 

  111. Truitt RL, Shih L, Leferer A. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in In AKR mice. Transplant 1986; 41:301–310.

    CAS  Google Scholar 

Download references

Authors
  1. Georgia B. Vogelsang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Houston, Texas, USA

    Richard Champlin M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Kluwer Academic Publishers

About this chapter

Cite this chapter

Vogelsang, G.B. (1990). Acute graft-versus-host disease. In: Champlin, R. (eds) Bone Marrow Transplantation. Cancer Treatment and Research, vol 50. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1493-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1493-6_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8803-9

  • Online ISBN: 978-1-4613-1493-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation